U.S. Healthtech Stock News

Coupang recently disclosed a major data breach that exposed the personal information of about 33.7 million customers, prompted executive resignations, triggered police raids on its Seoul headquarters, and left the company facing potential regulatory fines that could reach roughly US$0.77 billion under South Korea’s Personal Information Protection Act. While the incident has intensified scrutiny of Coupang’s data security and governance, it also comes at a time when the company has been...

Constellation Energy (CEG) has quietly been rewarding patient shareholders, with the stock up about 51% year to date and roughly 57% over the past year, handily beating the broader utilities space. See our latest analysis for Constellation Energy. That strength has not come out of nowhere, with a steady 30 day share price return of about 8 percent and a three year total shareholder return of roughly 328 percent pointing to investors repricing Constellation as a higher growth, lower risk...

Kroger (KR) has quietly slipped about 7 % over the past month, even as its long term returns still look solid. That pullback has investors asking whether the grocery giant is drifting or resetting. See our latest analysis for Kroger. At around $62.10 a share, Kroger’s recent 1 month share price return of roughly negative 7 percent looks more like a breather than a breakdown. This is especially the case given its 5 year total shareholder return above 120 percent, which suggests the longer term...

Wondering if Phibro Animal Health is still good value after its huge run, or if most of the upside is already priced in? This is where we break that down in plain English. The stock has climbed 5.5% over the last week and 94.9% year to date, even after a recent 10.4% pullback over the past month, leaving longer term holders with gains of 83.7% over 1 year and 243.1% over 3 years. Those swings have come as investors refocus on companies tied to animal health and food supply chains, lifting...

B of A Securities’ recent upgrade of Schrödinger (SDGR) to Buy, together with a broadly upbeat brokerage consensus, has pushed this computational drug discovery name back onto many investors’ radar. See our latest analysis for Schrödinger. The upbeat call from B of A comes after a choppy stretch, with the share price now at $17.94 and a year to date share price return of minus 12.06 percent alongside a one year total shareholder return of minus 16.01 percent. This suggests sentiment may be...

American Electric Power Company (AEP) has been drifting lower over the past month even as its year to date return stays comfortably positive, a setup that often makes utilities investors recheck the fundamentals. See our latest analysis for American Electric Power Company. That recent 5.55% one month share price pullback to about $114.57 looks more like a pause within a strong year to date share price return of 24.61%, backed by a nearly 29% one year total shareholder return that suggests...

Wondering if Allstate at around $209 a share is still a smart buy or if the easy money has already been made? This breakdown will help you decide whether the current price matches the company’s true value. After a 4.2% gain over the last week, Allstate is still up 9.1% year to date and 10.5% over the past year, adding to an already strong 68.1% 3 year and 123.1% 5 year run that has shifted how the market views its growth and risk profile. Much of this move has been underpinned by improving...

Criteo (CRTO) has quietly slid about 47% this year, even as its underlying ad tech business remains cash generative. That disconnect is prompting some investors to revisit the stock’s risk reward tradeoff. See our latest analysis for Criteo. Despite a steep year to date share price return of negative 46.9 percent, recent trading has steadied, with modest positive 1 day and 7 day share price returns hinting that heavy selling pressure may be easing while long term total shareholder returns...

Wondering if Cooper Companies is quietly turning into a value opportunity after a rough patch? This article will walk you through what the numbers are really saying about the stock. After sliding earlier this year, the share price has bounced about 3.2% in the last week and 12.4% over the last month, even though it is still down 10.6% year to date and 14.2% over the past year. That rebound has come as investors refocus on Cooper's positioning in specialty contact lenses and women's health,...

Earlier this month, Cadre Holdings’ Med-Eng subsidiary secured a 5-year US$50 million contract from the U.S. Department of War to support the Blast Exposure Monitoring Program, while President Brad Williams sold 24,000 shares worth about US$1,031,760 amid additional planned insider sales. The combination of a fresh multi-year government contract and sizeable insider selling highlights the tension investors may see between operational momentum and internal ownership changes. We’ll now explore...

Kraft Heinz has appointed former Kellanova chief Steve Cahillane as Chief Executive Officer and future head of its planned Global Taste Elevation Co., as current CEO Carlos Abrams-Rivera transitions to an advisory role through early 2026. The move brings in a leader with direct experience overseeing a major corporate separation and managing large global brands, aligning closely with Kraft Heinz’s plan to split into two independent, publicly traded companies in 2026. We’ll now examine how...

Wondering if JBS at around $14.34 is quietly trading below what it is really worth? You are not alone, and this breakdown is designed to help you decide if the stock deserves a spot on your watchlist. Over the last week JBS is up 3.5%, building on an 8.1% gain over the past month and a 3.4% rise year to date. These moves hint that investors are starting to reassess the company’s risk and growth profile. Recent headlines have focused on JBS’s ongoing push to streamline operations and invest...

Vertex Inc. recently expanded its long-standing partnership with CPA.com, adding Kintsugi’s AI technology to deliver an end-to-end, automated sales tax compliance application for accounting firms, which they showcased at the December 7–10 Digital CPA Conference in Washington, D.C. The integration of AI-driven exposure analysis, automated registration and filing, and white-labelled or fully outsourced compliance options could deepen Vertex’s reach into Client Advisory Services and State and...

If you are wondering whether Biogen is a quietly mispriced opportunity or a value trap in disguise, this breakdown walks through what the numbers are really saying about the stock. Biogen's share price has been choppy, down 2.5% over the last week but still up 2.4% over the past month and 14.3% year to date. This pattern hints at shifting market sentiment after years of lackluster longer term returns. Recent headlines around Biogen have focused on its push into new neurological treatments...

Wondering if Insight Enterprises is a beaten down opportunity or a value trap at today’s price? You are not the only one asking whether the current share price really reflects its underlying business. The stock has slid to around $79.62, with returns of about -6.3% over the last week, -11.6% over the last month, and a much steeper -46.7% year to date and -48.9% over the past year. This has reshaped how the market is pricing its future. Much of this shift has come as investors reassess IT...

Clorox (CLX) has quietly slid this year, with the stock down roughly 38% year to date and about 20% over the past 3 months, prompting investors to revisit its valuation. See our latest analysis for Clorox. That slide reflects more than just a bad week, with the latest share price of $99.82 and a steep year to date share price return signalling that momentum has clearly faded despite modest underlying revenue and net income growth. If Clorox’s pullback has you rethinking your watchlist, this...

Catalyst Pharmaceuticals (CPRX) has quietly delivered solid gains over the past few months, with the stock up around 7% in the past week and more than 20% over the past 3 months. See our latest analysis for Catalyst Pharmaceuticals. Zooming out, that recent upswing builds on a steady trend, with a roughly 12% year to date share price return and a powerful 5 year total shareholder return above 600%, suggesting momentum is still firmly on Catalyst Pharmaceuticals side at around 24 dollars and...

If you are wondering whether Dropbox is quietly turning into a value opportunity while many investors focus on flashier tech names, this breakdown is for you. The stock is down 2.8% over the last week, 5.8% over the last month, and 3.3% year to date, but it is still up 27.7% over three years and 15.0% over five years, which tells a very different longer term story. Recent headlines have focused on Dropbox sharpening its product focus and pushing harder into AI driven features and workflow...

If you have been wondering whether Corcept Therapeutics is still worth buying after its big run, you are not alone; this stock has quietly turned into one of the more intriguing valuation stories in biotech. The share price now sits around $81.12, with a 7.4% gain over the last month, a hefty 62.3% year to date, and a 295.3% return over three years that has clearly shifted how the market prices its future. Recent headlines have focused on Corcept's expanding clinical pipeline and regulatory...

If you are wondering whether Lattice Semiconductor at around $74.50 is still a smart buy or if most of the upside is already priced in, you are not alone, and that is exactly what we are going to unpack here. The stock has slipped about 4.4% over the last week, but it is still up 16.1% over the past month and 33.2% year to date, adding to a longer term gain of 70.4% over five years that has investors asking what comes next. Recent headlines have focused on Lattice's positioning in low power...

If you are wondering whether Kyivstar Group is still good value after its recent run up, or if you have already missed the boat, this breakdown will help you decide whether the current price makes sense. The stock has climbed 5.7% over the last week, 32.7% over the past month, and is now up roughly 51.0% year to date, which indicates that sentiment has shifted quickly. That momentum has come as investors refocus on Ukraine's critical digital infrastructure and the role Kyivstar plays in...

Gaming and Leisure Properties, Inc. recently appointed Michael Borofsky as a new independent director, expanding its board to eight members, seven of whom meet Nasdaq independence standards. Borofsky’s background in capital allocation, gaming investments, and complex transactions could influence how Gaming and Leisure Properties evaluates future deals, risk, and long-term capital deployment. Next, we’ll examine how adding Borofsky’s private equity and gaming experience to the board may...

AllianceBernstein Holding (AB) has been quietly grinding higher, with the stock up about 4% over the past 3 months and roughly 23% over the past year, outpacing many traditional asset managers. See our latest analysis for AllianceBernstein Holding. With the share price now around $39.85 and a 30 day share price return of 1.30 percent, the steadier 1 year total shareholder return of 22.82 percent suggests momentum is still building rather than fading. If you are weighing up where else...

In December 2025, Teva Pharmaceutical Industries obtained lender consent to extend the maturity of its senior unsecured sustainability-linked revolving credit facility from April 29, 2027, to April 29, 2028, while resetting key leverage and interest-cover covenants tied to potential Investment Grade Status. This covenant flexibility, together with recent progress in higher-margin branded and biosimilar products, gives Teva more room to align its balance sheet with its ongoing business...